[go: up one dir, main page]

PT100525A - Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem - Google Patents

Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem

Info

Publication number
PT100525A
PT100525A PT100525A PT10052592A PT100525A PT 100525 A PT100525 A PT 100525A PT 100525 A PT100525 A PT 100525A PT 10052592 A PT10052592 A PT 10052592A PT 100525 A PT100525 A PT 100525A
Authority
PT
Portugal
Prior art keywords
immunomodular
contain
pharmaceutical compositions
treatment
azaspiranes
Prior art date
Application number
PT100525A
Other languages
English (en)
Other versions
PT100525B (pt
Inventor
David S Garvey
Youe-Kong Shue
Stephen P Arneric
Nan-Horng Lin
George M Carrera Jr
Yun He
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of PT100525A publication Critical patent/PT100525A/pt
Publication of PT100525B publication Critical patent/PT100525B/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT100525A 1991-05-29 1992-05-28 Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem PT100525B (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70692091A 1991-05-29 1991-05-29

Publications (2)

Publication Number Publication Date
PT100525A true PT100525A (pt) 1993-09-30
PT100525B PT100525B (pt) 1999-10-29

Family

ID=24839628

Family Applications (1)

Application Number Title Priority Date Filing Date
PT100525A PT100525B (pt) 1991-05-29 1992-05-28 Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem

Country Status (13)

Country Link
US (1) US5409946A (pt)
EP (1) EP0588917B1 (pt)
JP (1) JP3153551B2 (pt)
AT (1) ATE197454T1 (pt)
BR (1) BR1100981A (pt)
CA (1) CA2109585C (pt)
DE (1) DE69231557T2 (pt)
DK (1) DK0588917T3 (pt)
ES (1) ES2153360T3 (pt)
GR (1) GR3035285T3 (pt)
IE (1) IE921690A1 (pt)
PT (1) PT100525B (pt)
WO (1) WO1992021339A1 (pt)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994010145A1 (en) * 1992-10-23 1994-05-11 Merck Sharp & Dohme Limited Dopamine receptor subtype ligands
US5424444A (en) * 1992-11-25 1995-06-13 Abbott Laboratories Method of preparing enantiomerically-pure 3-methyl-5-(1-alkyl-2(S)-pyrrolidinyl) isoxazoles
US5494680A (en) * 1993-12-08 1996-02-27 Minnesota Mining And Manufacturing Company Transdermal delivery device
US5677459A (en) * 1994-11-10 1997-10-14 Sibia Neurosciences, Inc. Methods for the preparation of modulators of acetylcholine receptors
US5594011A (en) * 1994-11-10 1997-01-14 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5703100A (en) * 1994-11-10 1997-12-30 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5705512A (en) * 1994-11-10 1998-01-06 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5723477A (en) * 1994-11-10 1998-03-03 Sibia Neurosciences, Inc. Modulators of acetylcholine receptors
US5824692A (en) * 1995-01-06 1998-10-20 Lippiello; Patrick Michael Pharmaceutical compositions for prevention and treatment of central nervous system disorders
DE19501022C1 (de) * 1995-01-14 1996-06-05 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Verabreichung von (s)-3-Methyl-5-(1-methyl-2-pyrrolidenyl)-isoxazol oder einem seiner pharmazeutisch akzeptablen Salze und Verfahren zu seiner Herstellung
AU5014396A (en) * 1995-03-24 1996-10-16 Japan Tobacco Inc. Diazabicyclo{3.3.1}nonane derivatives and intermediates ther eof, medicinal use of the same, and processes for producing the same
US6194581B1 (en) 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) * 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
US5794887A (en) 1995-11-17 1998-08-18 Komerath; Narayanan M. Stagnation point vortex controller
US5723414A (en) * 1996-01-24 1998-03-03 Rohm And Haas Company 5-aryl-isoxazolinones and herbicidal use thereof
CA2252515C (en) 1996-04-23 2006-11-07 R.J. Reynolds Tobacco Company Pharmaceutical compositions for prevention and treatment of central nervous system disorders
US5706829A (en) * 1996-06-06 1998-01-13 Creighton University Method for treating neurocardiogenic syncope
US5760049A (en) * 1997-02-21 1998-06-02 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
US6166032A (en) * 1997-02-07 2000-12-26 Synapse Pharmaceuticals International, Inc. Method for controlling tobacco use and alleviating withdrawal symptoms due to cessation of tobacco use
DK0984965T3 (da) * 1997-05-30 2004-09-27 Neurosearch As 8-azabicyclo[3.2.1]oct-2-enderivater som cholinerge ligander ved nikotin-ACh-receptorer
ATE229509T1 (de) 1997-05-30 2002-12-15 Neurosearch As Azacyclooktan- und heptan-derivate, ihre herstellung und ihre therapeutische verwendung
DE69811070T2 (de) * 1997-05-30 2003-10-02 Neurosearch A/S, Ballerup 9-azabicyclo(3.3.1)non-2-ene und nonanderivate als liganden der nicotinergen rezeptoren
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6133002A (en) 1997-09-25 2000-10-17 Dsm N.V. Process for preparing optically active 2-amino-ω-oxoalkanoic acid derivatives
US6218383B1 (en) 1998-08-07 2001-04-17 Targacept, Inc. Pharmaceutical compositions for the prevention and treatment of central nervous system disorders
AU2001247474A1 (en) * 2000-03-16 2001-09-24 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US7053064B2 (en) * 2002-11-08 2006-05-30 The Mclean Hospital Corporation Compounds for the treatment of tobacco dependence and withdrawal
CN100563660C (zh) * 2002-12-20 2009-12-02 麦克莱恩医院 用于正常化睡眠/觉醒周期的化合物
US20050113449A1 (en) * 2003-10-08 2005-05-26 Renshaw Perry F. Enhanced efficacy of omega-3 fatty acid therapy in the treatment of psychiatric disorders and other indications
CA2542023A1 (en) * 2003-10-08 2005-09-22 The Mclean Hospital Corporation Methods of treating psychiatric, substance abuse, and other disorders using combinations containing omega-3 fatty acids
ES2356356T3 (es) 2003-10-15 2011-04-07 Targacept, Inc. Compuestos azabicíclicos para aliviar el dolor y tratar los trastornos del sistema nervioso central.
FR2862647B1 (fr) * 2003-11-25 2008-07-04 Aventis Pharma Sa Derives de pyrazolyle, procede de preparation et intermediaires de ce procede a titre de medicaments et de compositions pharmaceutiques les renfermant
EP1765364A4 (en) * 2004-06-10 2010-09-22 Mclean Hospital Corp PYRIMIDINES, SUCH AS Z: B: CYTIDINE, IN THE TREATMENT OF PATIENTS WITH BIPOLAR DISORDER
WO2005122767A1 (en) * 2004-06-10 2005-12-29 Mclean Hospital Corporation Pyrimidines, such as uridine, in treatments for patients with bipolar disorder
EP1784199A4 (en) * 2004-08-11 2010-06-23 Mclean Hospital Corp COMPOUNDS FOR TREATING MARIHUANA DEPENDENCE, DEDUCTION AND CONSUMPTION
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
EP2322168A1 (en) 2007-04-02 2011-05-18 Parkinson's Institute Methods and Compositions for Reduction of Side Effects of Therapeutic Treatments
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
WO2010030887A1 (en) * 2008-09-11 2010-03-18 Catholic Healthcare West Nicotinic attenuation of cns inflammation and autoimmunity
EP2523944A4 (en) 2010-01-11 2013-06-19 Mithridion Inc COMPOUNDS AND COMPOSITIONS FOR IMPROVING COGNITION, METHODS OF MAKING THE SAME, AND METHODS OF TREATMENT
WO2012033956A1 (en) 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
KR20160081989A (ko) 2013-02-28 2016-07-08 더미라, 인코포레이티드 글리코피롤레이트 염
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
CA3049529A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
AU2019279884B2 (en) 2018-05-29 2025-01-30 Morningside Venture Investments Limited Drug delivery methods and systems
JP2022507660A (ja) 2018-11-16 2022-01-18 モーニングサイド ベンチャー インベストメンツ リミテッド 温度によって調節される経皮薬剤送達システム

Also Published As

Publication number Publication date
PT100525B (pt) 1999-10-29
WO1992021339A1 (en) 1992-12-10
ES2153360T3 (es) 2001-03-01
CA2109585A1 (en) 1992-12-10
EP0588917A1 (en) 1994-03-30
JP3153551B2 (ja) 2001-04-09
US5409946A (en) 1995-04-25
EP0588917A4 (pt) 1994-04-13
GR3035285T3 (en) 2001-04-30
JPH06508143A (ja) 1994-09-14
DK0588917T3 (da) 2001-02-12
EP0588917B1 (en) 2000-11-08
BR1100981A (pt) 2000-04-18
ATE197454T1 (de) 2000-11-11
IE921690A1 (en) 1992-12-02
DE69231557D1 (de) 2000-12-14
CA2109585C (en) 2000-02-15
DE69231557T2 (de) 2001-06-21

Similar Documents

Publication Publication Date Title
PT100525A (pt) Azaspiranos substituidos imunomodulares, seu uso e composicoes farmaceuticas que os contem
KR950702829A (ko) 신경계 퇴행성 질환의 치료에 유용한 아나바세인 유도체
PT100631A (pt) Antagonistas biciclicos de fibrinogenio, seu uso e composicoes farmaceuticas que os contem
DE69426331D1 (de) Arzneimittel gegen nervöse erkrankungen
DE3263734D1 (en) Derivatives of 1-aryl-2-aminomethyl-cyclopropane-carboxamides (z), their preparation and their use as medicines in the treatment of disorders of the central nervous system
ATE170530T1 (de) Thiazolidinderivate, ihre herstellung und medikamente, die sie enthalten
PT649846E (pt) Derivados da galantamina processo para a sua preparacao e sua utilizacao como medicamentos
ATE73785T1 (de) 5-(3-alkyl-5-tert.butyl-4-hydroxyphenyl)-2-amin - 6h-1,3,4-thiadiazine, verfahren zu ihrer herstellung, die sie enthaltenden arzneimittel und ihre verwendung.
DE69625709D1 (de) Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten
ATE23160T1 (de) Neue pyridobenzodiazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel.
SE8503109L (sv) Cykliska forstadielekemedel till antiinflammatoriska oxikamer
KR910000143A (ko) 간질치료제로서의 5-페닐-2- 푸란 에스테르 및 아미드의 용도
AU1621392A (en) New 1-amidooctahydropyrido(2,1-c)(1,4)oxazine compounds, processes for preparing these and pharmaceutical compositions containing them
DE59104473D1 (de) Arzneimittel welche substituierte 2-Cyclohexen-1yl-amin-Derivate enthalten und ihre Verwendung zur Bekämpfung von Krankheiten.
AU579416B2 (en) 3-Amino-2,3-dihydro-1-benzoxepine-compounds and methods for their preparation and pharmaceutical preparations containing these compounds
ATE83484T1 (de) 20,21-dinoreburnamenin-derivate, substituiert in position 15 durch eine aminogruppe und deren salze, verfahren zu deren herstellung und die auf diese weise erhaltenen zwischenverbindungen, deren anwendung als arzneimittel und diese enthaltende pharmazeutische zusammensetzungen.
TH18473A (th) การใช้เวนลาแฟกซีนหรือสารประกอบแอริลออกซิ โพรแพแนมีนในการผลิตยาสำหรับการรักษาการกลั้นปัสสาวะไม่อยู่
TH16153B (th) การใช้เวนลาแฟกซีนหรือสารประกอบแอริลออกซิ โพรแพแนมีนในการผลิตยาสำหรับการรักษาการกลั้นปัสสาวะไม่อยู่

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19930427

FG3A Patent granted, date of granting

Effective date: 19990707